Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary Disease Exacerbations in Type 2 Diabetes

This comparative effectiveness research study examines the outcomes of treatment with sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, or dipeptidyl peptidase-4 inhibitors for patients with type 2 diabetes and chronic obstructive pulmonary disease.

from JAMA Internal Medicine Online First https://ift.tt/rnaqZSH